Can scans predict muscle loss from popular diabetes drugs?
NCT ID NCT07156331
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will follow 20 adults with type 2 diabetes who are starting on semaglutide or tirzepatide. Researchers will use PET/CT scans and physical tests to track changes in muscle mass, strength, and bone health over one year. The goal is to find early warning signs of muscle or bone loss so doctors can take steps to prevent harm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide or tirzepatide
- What this could lead to
- If successful, this could help doctors predict who is at risk of muscle or bone loss from these diabetes drugs, leading to better monitoring and preventive care.
- What could go wrong
- This is a very small, early exploratory study with only 20 people, so results may not apply to everyone. It is designed to gather information, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?